Neurological development and iron supplementation in healthy late-preterm neonates: a randomized double-blind controlled trial

被引:0
作者
R. Luciano
D. M. Romeo
G. Mancini
S. Sivo
C. Dolci
C. Velli
A. Turriziani Colonna
G. Vento
C. Romagnoli
E. M. Mercuri
机构
[1] Fondazione Policlinico Universitario A. Gemelli,Neonatology Unit, Department of Woman and Child Health and Public Health, Child Health Area
[2] IRCCS,Pediatric Neurology Unit
[3] Catholic University of Sacred Heart,Department of Woman and Child Health and Public Health, Child Health Area
[4] Fondazione Policlinico A. Gemelli IRCCS,Neonatology Unit, Department of Woman and Child Health and Public Health, Child Health Area
[5] Catholic University of Sacred Heart,Pediatric Neurology Unit, Department of Woman and Child Health and Public Health, Child Health Area
[6] Fondazione Policlinico Universitario A. Gemelli,undefined
[7] IRCCS,undefined
[8] Fondazione Policlinico Universitario A. Gemelli,undefined
[9] IRCCS,undefined
[10] Catholic University of Sacred Heart,undefined
来源
European Journal of Pediatrics | 2022年 / 181卷
关键词
Late preterm; Psychomotor development; Iron deficiency; Iron supplementation;
D O I
暂无
中图分类号
学科分类号
摘要
Late-preterm infants (LPT) are at increased risk for long-term neurodevelopmental sequelae and iron deficiency. The aim of the study is to assess the positive effect of iron supplementation on psychomotor development in healthy LPT. We designed a randomized placebo-controlled double-blind trial dividing the newborns into two groups. Every patient was assessed using the Griffiths Mental Development Scales (GMDS)-II edition at 12-month post-conceptional age. The study was performed at the Neonatology Unit of our Hospital, in Italy. Sixty-six healthy LPT infants born between 340⁄7 and 366⁄7 weeks of gestational age were enrolled in the study. One group received martial prophylaxis from the third week of life to 6 months of post-conceptional age (2 mg/kg/day of iron pidolate), the other received placebo. Fifty-two of the enrolled infants were assessed using the GMDS at 12-month of post-conceptional age. Statistical analysis of the mean scores of the Griffiths subscales was performed. There was a difference in the mean developmental quotient (DQ) (p < 0.01) between the two groups: iron group mean DQ 121.45 ± 10.53 vs placebo group mean DQ 113.25 ± 9.70. Moreover, mean scores of the Griffiths subscales A, B, and D showed significant differences between the two groups (scale A p < 0.05, scale B p < 0.02, scale D p < 0.01, respectively).
引用
收藏
页码:295 / 302
页数:7
相关论文
共 50 条
[41]   Increasing Natural Killer Cell Activity of Mineral Nanomaterial ALP1018 in Healthy Adults: A Randomized, Double-Blind, Placebo Comparative Clinical Trial [J].
Kim, Soon-Ae ;
Kim, Seyl ;
Chai, Hyungyung ;
Cho, Junlae ;
Paek, Yu-Jin .
NUTRIENTS, 2024, 16 (06)
[42]   Does antenatal micronutrient supplementation improve children's cognitive function? Evidence from the follow-up of a double-blind randomised controlled trial in Nepal [J].
Dulal, Sophiya ;
Liegeois, Frederique ;
Osrin, David ;
Kuczynski, Adam ;
Manandhar, Dharma S. ;
Shrestha, Bhim P. ;
Sen, Aman ;
Saville, Naomi ;
Devakumar, Delan ;
Prost, Audrey .
BMJ GLOBAL HEALTH, 2018, 3 (01)
[43]   A double blind randomised controlled trial comparing standard dose of iron supplementation for pregnant women with two screen-and-treat approaches using hepcidin as a biomarker for ready and safe to receive iron [J].
Bah, Amat ;
Wegmuller, Rita ;
Cerami, Carla ;
Kendall, Lindsay ;
Pasricha, Sant-Rayn ;
Moore, Sophie E. ;
Prentice, Andrew M. .
BMC PREGNANCY AND CHILDBIRTH, 2016, 16
[44]   A double blind randomised controlled trial comparing standard dose of iron supplementation for pregnant women with two screen-and-treat approaches using hepcidin as a biomarker for ready and safe to receive iron [J].
Amat Bah ;
Rita Wegmuller ;
Carla Cerami ;
Lindsay Kendall ;
Sant-Rayn Pasricha ;
Sophie E. Moore ;
Andrew M. Prentice .
BMC Pregnancy and Childbirth, 16
[45]   A novel nano-iron supplement versus standard treatment for iron deficiency anaemia in children 6-35 months (IHAT-GUT trial): a double-blind, randomised, placebo-controlled non-inferiority phase II trial in The Gambia [J].
Mohammed, Nuredin I. ;
Wason, James ;
Mendy, Thomas ;
Nass, Stefan A. ;
Ofordile, Ogochukwu ;
Camara, Famalang ;
Baldeh, Bakary ;
Sanyang, Chilel ;
Jallow, Amadou T. ;
Hossain, Ilias ;
Faria, Nuno ;
Powell, Jonathan J. ;
Prentice, Andrew M. ;
Pereira, Dora I. A. .
ECLINICALMEDICINE, 2023, 56
[46]   Effectiveness of intermittent iron and high-dose vitamin A supplementation on cognitive development of school children in southern Ethiopia: a randomized placebo-controlled trial [J].
Gutema, Befikadu Tariku ;
Levecke, Bruno ;
Sorrie, Muluken Bekele ;
Megersa, Nega Degefa ;
Zewdie, Tadiwos Hailu ;
Yesera, Gesila Endashaw ;
De Henauw, Stefaan ;
Abubakar, Amina ;
Abbeddou, Souheila .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2024, 119 (02) :470-484
[47]   Consumption of a calcium and vitamin D-fortified food product does not affect iron status during initial military training: a randomised, double-blind, placebo-controlled trial [J].
Hennigar, Stephen R. ;
Gaffney-Stomberg, Erin ;
Lutz, Laura J. ;
Cable, Sonya J. ;
Pasiakos, Stefan M. ;
Young, Andrew J. ;
McClung, James P. .
BRITISH JOURNAL OF NUTRITION, 2016, 115 (04) :637-643
[48]   A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the effect of consuming Growing Up Milk "Lite" on body composition in children aged 12-23 mo [J].
Wall, Clare R. ;
Hill, Rebecca J. ;
Lovell, Amy L. ;
Matsuyama, Misa ;
Milne, Tania ;
Grant, Cameron C. ;
Jiang, Yannan ;
Chen, Rachel X. ;
Wouldes, Trecia A. ;
Davies, Peter S. W. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2019, 109 (03) :576-585
[49]   The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study [J].
Kassianides, Xenophon ;
Bhandari, Sunil .
BMC NEPHROLOGY, 2024, 25 (01)
[50]   The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD – the exploratory randomized controlled double-blind ExplorIRON-CKD study [J].
Xenophon Kassianides ;
Sunil Bhandari .
BMC Nephrology, 25